Name

Jupiter Neurosciences

Legal name

Jupiter Neurosciences, Inc.

Website

https://jupiterneurosciences.com

Company type

Public

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Neurology Pharmaceuticals (CNS Therapeutics)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Neurology pharmaceuticals
• CNS therapeutics
• Resveratrol drug delivery
• Consumer longevity supplements
• Clinical-stage biotech

Headquarters

HQ city

Palm Beach Gardens

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Consumer Wellness Products (Nugevia): Jupiter launched its Nugevia consumer longevity supplement brand direct-to-consumer, utilizing the same JOTROL enhanced formulation for longevity and health support. Initial sales started in late 2025. The product line includes three formulations and targets the $1.5 billion U.S. nutraceutical market with subscription-based sales showing approximately 25% repeat purchase rates.
2. Licensing and Milestone Payments (ALA-002): Jupiter Neurosciences signed a $100M term sheet to acquire exclusive U.S. licensing rights to ALA-002 for $3.33 million upfront ($1.5M cash plus $1.83M in JUNS shares), plus additional development milestone payments and single-digit royalties on net sales.
3. Clinical Development Revenue: The company is developing CNS disorder treatments centered on its proprietary resveratrol formulation JOTROL™ and is conducting Phase IIa trials for Parkinson's disease. Revenue potential exists upon successful clinical development and regulatory approval.
4. Financing Agreements: Jupiter secured up to $20 million in financing from Yorkville Advisors, including a $6 million pre-paid advance and up to $14 million under a standby equity purchase agreement, to support Parkinson's clinical trials and growth initiatives.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

Jupiter Neurosciences develops and commercializes JOTROL™, a proprietary micellar resveratrol delivery platform that enables oral administration of therapeutic-dose resveratrol without gastrointestinal side effects, currently in Phase IIa clinical trials for Parkinson's disease and being developed for Alzheimer's disease, Friedreich's Ataxia, and mucopolysaccharidosis Type I. The company also sells Nugevia™, a direct-to-consumer longevity supplement line utilizing the same JOTROL technology, and holds exclusive U.S. licensing rights to ALA-002, a next-generation MDMA therapeutic.

Product overview

Jupiter Neurosciences is a clinical-stage pharmaceutical company operating a dual-path strategy combining clinical drug development with consumer product commercialization. The core technology platform is JOTROL™, a patented micellar resveratrol delivery system that enables therapeutic-level dosing without gastrointestinal side effects—a limitation that has historically prevented resveratrol from reaching clinical efficacy. JOTROL™ forms the foundation of the therapeutic pipeline, currently advancing through a Phase IIa trial for Parkinson's disease while also being developed for Alzheimer's disease, Friedreich's Ataxia, and mucopolysaccharidosis Type I. The same JOTROL™ technology powers Nugevia™, a direct-to-consumer longevity supplement brand launched in late 2025, representing the company's commercial revenue strategy. A third product pillar, ALA-002, was added in 2026 through a $100M licensing deal for a next-generation MDMA therapeutic.

Differentiator

Problem solved

Functional benefit

Brands

• Nugevia: Direct-to-consumer longevity supplement product line utilizing JOTROL micellar delivery technology, targeting the $1.5 billion US nutraceutical market. Product line includes three formulations and is available direct-to-consumer with approximately 25% repeat purchase rates and 3% product return rates.
• JOTROL

Products and services

• JOTROL™ JOTROL™ is a proprietary resveratrol-based drug delivery platform using patented micellar technology that enables resveratrol to safely reach therapeutic plasma levels (300 ng/ml at C-Max) without gastrointestinal side effects. Delivered as an oral softgel, it can cross the blood-brain barrier for CNS treatment and is being developed for Parkinson's disease (Phase IIa), Alzheimer's disease, Friedreich's Ataxia, and mucopolysaccharidosis Type I.
• Nugevia™ Nugevia™ is a direct-to-consumer longevity supplement product line utilizing the proprietary JOTROL micellar delivery technology for enhanced resveratrol bioavailability. The line includes three formulations targeting the $1.5 billion U.S. nutraceutical market, with approximately 25% repeat purchase rates and 3% return rates, and is sold via subscription and unit pricing through the company's e-commerce storefront.
• ALA-002 (U.S. Licensed Rights) ALA-002 is a next-generation MDMA therapeutic developed by PharmAla Biotech, recognized as an FDA Novel Chemical Entity with improved cardiovascular safety and reduced abuse liability compared to traditional MDMA. Jupiter acquired exclusive U.S. licensing rights in a transaction valued at over $100 million, targeting the emerging psychedelic therapeutics market for neuropsychiatric conditions.

Quantifiable outcome

• Therapeutic resveratrol plasma level of 300 ng/ml at C-Max achieved with JOTROL™
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core, moderate and minor.

• PharmAla Biotech Holdings Inc.coreStrategic or Co-development Partner · 20 May 2026PharmAla signed a term sheet to grant Jupiter exclusive U.S. licensing rights to ALA-002, its lead next-generation MDMA drug candidate, in a transaction valued at over $100 million. Terms include $3.33 million upfront ($1.5M cash + $1.83M in JUNS shares) plus milestone payments and single-digit royalties. PharmAla retains all rights outside the U.S.
• ANNIKA Women's All Pro TourmoderateGTM or Marketing Partner · 18 February 2026Multi-year partnership designating Nugevia as the Official Supplement of the tour. Includes sponsorship of Nugevia PWR Athlete of the Year award, product support to athletes, and educational materials on nutrition and recovery throughout the season.
• Murdoch Children's Research InstituteminorStrategic or Co-development PartnerResearch collaboration partner listed on Jupiter's website partnerships section.
• Fara (CureFA)minorStrategic or Co-development PartnerPatient advocacy and research partnership for Friedreich's Ataxia, listed as a company partner.
• Syneos HealthminorImplementation/ SI/ Consulting PartnerClinical research organization partner providing clinical development services, listed as a company partner.
• The Picower Institute for Learning and Memory (MIT)minorStrategic or Co-development PartnerScientific advisory board partnership with Li-Huei Tsai, Director of the Picower Institute at MIT. The institute is listed as a company partner.
• Georgetown UniversityminorStrategic or Co-development PartnerAcademic partnership with Georgetown University Medical Center for scientific advisory board members Raymond Scott Turner and Charbel Moussa. Listed as a company partner.
• University of Miami Miller School of MedicineminorStrategic or Co-development PartnerAcademic partnership including scientific advisory board members and Dr. Wahlestedt's role as Leonard M. Miller Professor & Associate Dean for Therapeutic Innovation.
• Harvard UniversityminorStrategic or Co-development PartnerAcademic research partnership listed as a company partner, supporting the scientific advisory board network.
• Tech-Res (Tri Challenge)minorImplementation/ SI/ Consulting PartnerClinical research and regulatory affairs consulting partner listed as a company partner.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cassava Sciences: Clinical-stage biotech (NASDAQ: SAVA) focused on Alzheimer's disease therapeutics. Closely comparable as a small-cap, CNS-focused clinical development company with a single platform asset targeting neurodegenerative disease.
• BioVie: Clinical-stage CNS biotech developing therapies for neurodegenerative and neuroinflammatory conditions, including a Parkinson's program. Comparable in stage, target indication, and small-cap profile.
• Annovis Bio: Clinical-stage biotech developing neurodegenerative disease therapeutics for Parkinson's and Alzheimer's. Comparable as a small-cap, neuroscience-focused clinical developer with overlapping indications to JOTROL™.
• PharmAla Biotech Holdings: MDMA-focused clinical developer and Jupiter's counterparty on the ALA-002 licensing deal. Directly comparable as a psychedelic-therapeutics developer targeting the same regulatory opening Jupiter is positioning behind.

Broad incumbents

• Axsome Therapeutics: Commercial-stage CNS specialty pharma (NASDAQ: AXSM) with approved neurology products. Comparable as a CNS-focused specialty pharma, though larger and commercially established versus Jupiter's clinical-stage status.
• Intra-Cellular Therapies: CNS specialty pharma (NASDAQ: ITCI) with approved neuropsychiatric products and an active neurology pipeline. Comparable as a CNS specialty pharma at a more advanced commercial stage.
• Acadia Pharmaceuticals: Commercial CNS specialty pharma (NASDAQ: ACAD) with neurology and rare-disease franchises. Comparable as an established player in CNS specialty pharmaceuticals serving overlapping patient populations.
• Sage Therapeutics: CNS-focused biopharma (NASDAQ: SAGE) developing neurological and neuropsychiatric therapies. Comparable in neuroscience focus and indication overlap, though at a more advanced commercial stage.

Emerging players

• ChromaDex: Public longevity/wellness ingredient company (NASDAQ: CDXC) focused on NAD-precursor supplements. Comparable as a publicly traded science-backed longevity supplement business competing for share of the $1.5B+ U.S. nutraceutical market alongside Nugevia.
• Elysium Health: Direct-to-consumer longevity supplement company founded by longevity researchers. Comparable as a science-positioned consumer longevity brand targeting the same health-conscious buyer as Nugevia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/jupiterneurosciences
• Xx.com/jupiterorphan
• Facebookfacebook.com/jupiterorphantherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jupiter Neurosciences